natgillin/translations-raw huggingface dataset:
Thus, CYP450 expression may be reversed when potent cytokine inhibitory therapy, such as canakinumab, is introduced.
Stoga se ekspresija CYP450 može vratiti kada se uvede potentni lijek za inhibiranje citokina, kao što je kanakinumab.
Do not use if the liquid contains easily visible particles, is cloudy or is distinctly brown.
Nemojte koristiti tekućinu ako sadrži lako vidljive čestice, ako je zamućena ili izrazito smeđa.
Mild and transient Grade 1 reduction in platelets occurred in 15.9% of patients without any associated bleeding adverse events.
Blaga i prolazna smanjenja broja trombocita stupnja 1 javila su se u 15,9% bolesnika bez bilo kakvih uz to vezanih štetnih događaja krvarenja.
Treatment with canakinumab resulted in a rapid and sustained improvement of both the articular and the systemic features of SJIA with significant reduction of the number of inflamed joints, prompt resolution of fever and reduction of acute phase reactants in the majority of patients (see Clinical efficacy and safety).
Liječenje kanakinumabom rezultiralo je brzim i održanim poboljšanjem i artikularnih i sistemskih karakteristika SJIA-e uz značajno smanjenje broja upaljenih zglobova, brzo povlačenje vrućice i smanjenje reaktanata akutne faze u većine bolesnika (vidjeti Kliničku djelotvornost i sigurnost).
Within each system organ class, the adverse reactions are ranked by frequency category with the most common first.
Unutar svake klasifikacije organskog sustava nuspojave su navedene prema kategoriji učestalosti, počevši od najčešćih.
Make sure 1.0 ml of water is in the syringe, then take the needle out of the vial.
Provjerite da je u štrcaljki 1,0 ml vode, a zatim izvucite iglu iz bočice.
The AUCss4w in each age group was 692, 615, 707 and 742 µg*d/ml for 2-3, 4-5, 6-11, and 12-19 years old, respectively.
AUCss u svakoj dobnoj skupini bio je 692, 615, 707 odnosno 742 µg*d/ml za dobne skupine 2-3, 4-5, 6-11, odnosno 12-19 godina.
Do not inject into scar tissue as this may mean you do not get all of your medicine.
Ne ubrizgavajte u ožiljkasto tkivo budući da bi to moglo značiti da nećete dobiti sav svoj lijek.
Based on the population pharmacokinetic modelling analysis, the expected exposures after a dose of 2 mg/kg were comparable across the CAPS paediatric age groups, but were approximately 40% lower in paediatric patients of very low body weight (e.g. 10 kg) than in adult patients (150 mg dose).
Na temelju analize populacijskog farmakokinetičkog modeliranja, očekivana izloženost nakon doze od 2 mg/kg bila je usporediva po pedijatrijskim skupinama s CAPS-om, no bila je otprilike 40% niža u pedijatrijskih bolesnika vrlo niske tjelesne težine (npr. 10 kg) u odnosu na odrasle bolesnike (doza od 150 mg).
These crystals cause excessive production of IL-1 beta, which in turn can lead to sudden, severe pain, redness, warmth and swelling in a joint (known as a gouty arthritis attack).
Ti kristali uzrokuju prekomjerno stvaranje IL-1 beta, što pak može dovesti do iznenadne teške boli, crvenila, vrućine i oticanja zgloba (to se zove napad uričnog artritisa).
Part I: A complete clinical and biomarker response to canakinumab (defined as composite of physician's global assessment on autoinflammatory and on skin disease ≤ minimal and CRP or SAA values < 10 mg/litre) was observed in 97% of patients and appeared within 7 days of initiation of treatment.
I. dio: Potpun klinički odgovor i odgovor biomarkera na kanakinumab (definiran kao spoj liječnikove ukupne procjene autoinflamatorne i kožne bolesti ≤ minimalnog i vrijednosti CRP-a ili SAA <10 mg/litra) zabilježen je kod 97% bolesnika i pojavio se u roku od 7 dana od početka liječenja.
However, administration of live vaccines to newborn infants exposed to canakinumab in utero is not recommended for 16 weeks following the mother's last dose of canakinumab before childbirth.
Međutim, primjena živih cjepiva u novorođenčadi koja je bila izložena kanakinumabu in utero se ne preporučuje tijekom 16 tjedana nakon zadnje doze kanakinumaba koju je majka primila prije poroda.
Injection site reaction (such as redness, swelling, warmth and itching).
Reakcije na mjestu primjene injekcije (kao što su crvenilo, oticanje, toplina i svrbež).
An increased dose was administered more frequently to patients aged 2 to < 4 years and to patients with NOMID/CINCA symptoms compared with FCAS or MWS.
Povećana doza primjenjivala se učestalije kod bolesnika u dobi od 2 do <4 godine i kod bolesnika sa simptomima NOMID-a/CINCA-e u usporedbi sa FCAS-om ili MWS-om.
For children given a starting dose of 4 mg/kg who have not responded well enough after 7 days, the doctor may give a second dose of 4 mg/kg.
Za djecu koja su dobila početnu dozu od 4 mg/kg i koja nisu imala dovoljno dobar odgovor nakon 7 dana, liječnik može dati drugu dozu od 4 mg/kg.
Asymptomatic and mild elevations of serum bilirubin have been observed in CAPS patients treated with canakinumab without concomitant elevations of transaminases.
Asimptomatska i blaga povišenja serumskog bilirubina zabilježena su kod bolesnika s CAPS-om liječenih kanakinumabom bez istodobnih povišenja transaminaza.
- Part IV: All Part III patients treated with canakinumab were eligible to enter into a 72-week open-label treatment extension period.
- IV. dio: svi bolesnici iz III. dijela liječeni kanakinumabom mogli su se uključiti u 72-tjedni otvoreni produžetak ispitivanja.
Do not inject into scar-tissue as this may mean you do not get all of your medicine.
Ne ubrizgavajte u ožiljkasto tkivo jer bi to moglo značiti da nećete dobiti sav svoj lijek.
In the pooled efficacy analysis for these two studies, 65.6% of patients who had not previously been treated with canakinumab achieved complete response at 150 mg or 2 mg/kg, while 85.2% of patients achieved complete response at any dose.
U objedinjenoj analizi djelotvornosti za ta dva ispitivanja 65,6% bolesnika koji prethodno nisu bili liječeni kanakinumabom postiglo je potpuni odgovor pri dozi od 150 mg ili 2 mg/kg, dok je 85,2% bolesnika postiglo potpuni odgovor pri bilo kojoj dozi.
This product information has been updated to include the results of studies with Ilaris in the paediatric population.
Ovaj je sažetak ažuiriran kako bi uključivao rezultate ispitivanja s Ilarisom u pedijatrijskoj populaciji.
Your baby should not receive live vaccines until at least 16 weeks after you received your last dose of canakinumab before giving birth.
Vaše dijete ne smije primiti živa cjepiva dok ne prođe najmanje 16 tjedana od Vaše zadnje doze kanakinumaba koju ste primili prije poroda.
Still's disease including AOSD and SJIA is an inflammatory disease that can cause pain, swelling and inflammation of one or more joints, as well as rash and fever.
Stillova bolest, uključujući SBOD i SJIA, je upalna bolest koja može uzrokovati bol, oticanje i upalu jednog ili više zglobova, kao i osip i vrućicu.
In the Phase I/II study, treatment with canakinumab had a rapid onset of action, with disappearance or clinically significant improvement of symptoms within one day after dosing.
U ispitivanju faze I/II liječenje kanakinumabom imalo je brzi nastup djelovanja, uz nestanak ili klinički značajno poboljšanje simptoma u roku od jednog dana od primitka doze.
The Marketing Authorisation Holder has completed four Paediatric Investigation Plans for Ilaris (for CAPS, SJIA, FMF - HIDS/MKD and TRAPS respectively).
Nositelj odobrenja dovršio je četiri Plana pedijatrijskih ispitivanja za Ilaris (za CAPS, SJIA, FMFHIDS/MKD odnosno TRAPS).
What Ilaris is used for Ilaris is used for treatment of the following inflammatory diseases: - Periodic fever syndromes:
Za što se koristi Ilaris Ilaris se koristi za liječenje sljedećih upalnih bolesti: - sindromi periodičnih vrućica:
If not used immediately, the solution should be stored in the refrigerator (2°C - 8°C) and used within 24 hours.
Ako se ne upotrijebi odmah, otopinu je potrebno čuvati u hladnjaku (2°C - 8°C) i upotrijebiti u roku od 24 sata.
In an exploratory analysis of the primary endpoint, it was observed that in patients with an inadequate response after the first dose, an up-titration within the first month to a dose of 300 mg (or 4 mg/kg) every 4 weeks further improved flare control, reduced disease activity and normalised CRP and SAA levels.
U eksploratornoj analizi primarne mjere ishoda opaženo je da je u bolesnika s nedostatnim odgovorom nakon prve doze postupno povećanje doze unutar prvog mjeseca do doze od 300 mg (ili 4 mg/kg) svaka 4 tjedna dodatno poboljšalo kontrolu razbuktavanja, smanjilo aktivnost bolesti i normaliziralo razine CRP-a i SAA.
Gouty arthritis: If you have a gouty arthritis attack, you will be given a single dose of Ilaris.
Urični artritis: Ako imate napad uričnog artritisa, dobit ćete jednokratnu dozu Ilarisa.
For gouty arthritis, the physician should be experienced in the use of biologics and Ilaris should be administered by a healthcare professional.
Za urični artritis, liječnik mora imati iskustva s primjenom bioloških lijekova te Ilaris mora primjenjivati zdravstveni djelatnik.
The safety profile of canakinumab appeared similar to that in patients aged 2 years and above.
Sigurnosni profil kanakinumaba činio se sličan onome u bolesnika u dobi od 2 i više godina.
A total of 225 patients were treated with subcutaneous canakinumab 150 mg and 229 patients were treated with intramuscular triamcinolone acetonide (TA) 40 mg at study entry, and when experiencing a new attack thereafter.
Ukupno je 225 bolesnika liječeno supkutanim kanakinumabom 150 mg, a 229 bolesnika je liječeno intramuskularnim triamcinolon acetonidom (TA) 40 mg na početku ispitivanja, te nakon toga u slučaju novog napada.
Transient and asymptomatic cases of elevations of serum transaminases or bilirubin have been reported in clinical trials (see section 4.8).
U kliničkim ispitivanjima zabilježeni su prolazni i asimptomatski slučajevi povišenja serumskih transaminaza ili bilirubina (vidjeti dio 4.8).
• 150 mg for patients who weigh more than 40 kg
• 150 mg za bolesnike koji su teži od 40 kg
Resolution of disease flare was achieved by week 5 and the patient had not experienced any new flare at the end of Part II of the study (week 16).
Povlačenje razbuktavanja bolesti postignuto je do 5. tjedna i bolesnik nije doživio nikakvo novo razbuktavanje bolesti na kraju II. dijela ispitivanja (16. tjedan).
In the overall study population, patients on ULT had a less pronounced treatment difference in both pain reduction and reduction in the risk of subsequent gouty arthritis attacks compared to patients not on ULT.
U cjelokupnoj ispitivanoj populaciji bolesnici koji su primali ULT imali su manje izraženu terapijsku razliku kako u smanjenju boli tako i u smanjenju rizika od naknadnih napada artritisa u usporedbi s bolesnicima koji nisu primali ULT.
The apparent volume of distribution per kg (V/F per kg) was 0.14 l/kg.
Prividni volumen distribucije po kg (V/F po kg) bio je 0,14 l/kg.
Find a clean place in which to prepare and administer the injection.
Pronađite čisto mjesto na kojem ćete pripremiti i primijeniti injekciju.
The co-primary endpoints were: (i) gouty arthritis pain intensity (visual analogue scale, VAS) at 72 hours post-dose, and (ii) time to first new gouty arthritis attack.
Suprimarne mjere ishoda bile su: (I) intenzitet boli uričnog artritisa (vizualna analogna skala, VAS) 72 sata nakon doze te (II) vrijeme do prvog novog napada uričnog artritisa.
Part II: In the withdrawal period of the pivotal study, the primary endpoint was defined as the proportion of patients with a disease relapse/flare: none (0%) of the patients randomised to canakinumab flared, compared with 81% of the patients randomised to placebo.
II. dio: U razdoblju ustezanja u ključnom ispitivanju primarna mjera ishoda bila je definirana kao udio bolesnika s relapsom/razbuktavanjem bolesti: nijedan (0%) od bolesnika randomiziranih na kanakinumab nije imao razbuktavanje bolesti, u usporedbi s 81% bolesnika randomiziranih na placebo.
Ilaris is used in adults to treat the symptoms of frequent gouty arthritis attacks if other treatments have not worked well enough.
Ilaris se primjenjuje kod odraslih osoba za liječenje simptoma učestalih napada uričnog artritisa ako ostale terapije nisu dovoljno dobro djelovale.
If a patient becomes neutropenic or leukopenic, the WBC counts should be monitored closely and treatment discontinuation should be considered.
Ako se kod bolesnika javi neutropenija ili leukopenija, broj Lkc treba pažljivo kontrolirati te razmotriti prekid liječenja.
There were no antibodies against Ilaris observed in TRAPS, HIDS/MKD and FMF patients treated with doses of 150 mg and 300 mg over 16 weeks of treatment.
Nije bilo protutijela protiv Ilarisa opaženih u bolesnika s TRAPS-om, HIDS/MKD-om i FMF-om liječenih dozama od 150 mg i 300 mg tijekom 16 tjedana liječenja.
Gouty arthritis is caused by the formation of urate crystals.
Urični artritis je uzrokovan stvaranjem kristala urata u tijelu.
Carefully withdraw the required volume depending on the dose to be administered (0.1 ml to 1 ml) and subcutaneously inject using a 27 G x 0.5 inch (13 mm) needle.
Pažljivo izvucite potreban volumen ovisno o dozi koju treba primijeniti (0,1 ml do 1 ml) i injicirajte supkutano koristeći iglu od 27 G x 13 mm.
Never re-use the leftover solution.
Nikada nemojte ponovno upotrebljavati preostalu otopinu.
Overall, 33% (25/75) of patients randomised to dose reduction or dose interval prolongation arms were able to discontinue treatment with canakinumab and maintain inactive disease status for 6 months.
Općenito, 33% (25/75) bolesnika randomiziranih na smanjenje doze ili produljenje intervala doziranja uspjeli su prekinuti liječenje kanakinumabom i održati status neaktivne bolesti 6 mjeseci.
Significant improvements were seen in physician's clinical assessment of autoinflammatory disease activity: global assessment of autoinflammatory disease activity, assessment of skin disease (urticarial skin rash), arthralgia, myalgia, headache/migraine, conjunctivitis, fatigue/malaise, assessment of other related symptoms, and patient's assessment of symptoms.
Značajna poboljšanja uočena su u liječnikovoj kliničkoj procjeni aktivnosti autoinflamatorne bolesti: ukupna procjena aktivnosti autoinflamatorne bolesti, procjena kožne bolesti (urtikarijski kožni osip), artralgija, mijalgija, glavobolja/migrena, konjunktivitis, umor/malaksalost, procjena drugih povezanih simptoma i bolesnikova procjena simptoma.
Use of canakinumab with TNF inhibitors is not recommended because this may increase the risk of serious infections.
Primjena kanakinumaba s inhibitorima TNF-a ne preporučuje se zato što bi mogla povećati rizik od ozbiljnih infekcija.
- Keep this medicine out of the sight and reach of children.
Lijek čuvajte izvan pogleda i dohvata djece.
After repeated subcutaneous administration of 150 mg every 4 weeks, canakinumab minimal concentration at week 16 (Cmin) was estimated to be 15.4 ± 6.6 g/ml.
Nakon ponovljene supkutane primjene 150 mg svaka 4 tjedna, procijenjeno je da minimalna koncentracija kanakinumaba u 16. tjednu (Cmin) iznosi 15,4 ± 6,6 g/ml.
No data are available on the risk of secondary transmission of infection by live (attenuated) vaccines in patients receiving canakinumab.
Nema dostupnih podataka o riziku od sekundarnog prijenosa infekcije živim (atenuiranim) cjepivima kod bolesnika koji primaju kanakinumab.
Macrophage activation syndrome (MAS) is a known, life-threatening disorder that may develop in patients with rheumatic conditions, in particular Still's disease.
Sindrom aktivacije makrofaga (engl. macrophage activation syndrome; MAS) poznat je, po život opasan poremećaj koji se može razviti u bolesnika s reumatskim bolestima, osobito Stillovom bolešću.
Of the patients in clinical remission who continued with further dose reduction (1 mg/kg every 4 weeks) or dose interval prolongation (4 mg/kg every 12 weeks), 93% (26/28) and 91% (30/33) of patients, respectively, were able to maintain inactive disease status for 6 months.
Od bolesnika u kliničkoj remisiji koji su nastavili s dodatnim smanjenjem doze (1 mg/kg svaka 4 tjedna) ili produljenjem intervala doziranja (4 mg/kg svakih 12 tjedana), 93% (26/28), odnosno 91% (30/33) bolesnika uspjelo je održati status neaktivne bolesti 6 mjeseci.
Canakinumab binds with high affinity specifically to human IL-1 beta and neutralises the biological activity of human IL-1 beta by blocking its interaction with IL-1 receptors, thereby preventing IL-1 beta-induced gene activation and the production of inflammatory mediators.
Kanakinumab se veže visokim afinitetom specifično za humani IL-1 beta i neutralizira biološku aktivnost humanog IL-1 beta tako što blokira njegovu interakciju s receptorima za IL-1 te tako sprječava aktivaciju gena koju inducira IL-1 beta i stvaranje upalnih posrednika.
Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks (see section 4.5).
Stoga se živa cjepiva ne smiju davati istodobno s kanakinumabom, osim ako koristi očigledno ne premašuju rizike (vidjeti dio 4.5).
Formal carcinogenicity studies have not been conducted with canakinumab.
Formalna ispitivanja kancerogenosti nisu se provodila s kanakinumabom.
Therefore, live vaccines should not be given concurrently with canakinumab unless the benefits clearly outweigh the risks.
Stoga se živa cjepiva ne smiju davati istodobno s kanakinumabom osim ako je jasno da koristi premašuju rizike.
The mean change in pain score among canakinumab treated patients was consistent at day 29.
Srednja promjena u rezultatu za bol među bolesnicima liječenim kanakinumabom bila je dosljedna nakon 29 dana.
The most frequent adverse drug reactions were infections predominantly of the upper respiratory tract.
Najučestalije nuspojave na lijek bile su infekcije pretežno gornjeg dijela dišnog sustava.
Concomitant use of canakinumab with tumour necrosis factor (TNF) inhibitors is not recommended because this may increase the risk of serious infections (see section 4.5).
Istodobna primjena kanakinumaba s inhibitorima tumor nekrotizirajućeg faktora (TNF) se ne preporučuje jer bi to moglo povećati rizik od ozbiljnih infekcija (vidjeti dio 4.5).
It is not known whether Ilaris passes into human milk.
Nije poznato izlučuje li se Ilaris u majčino mlijeko.
Although reductions in platelet count (≥ Grade 2) occurred in 0.6% of patients, bleeding has not been identified as an adverse reaction.
Iako su se smanjenja broja trombocita (≥ stupnja 2) javila u 0,6% bolesnika, krvarenje nije utvrđeno kao nuspojava.
The incidence of patients with triglyceride elevations > 5 x upper limit of normal (ULN) was 2.4% with canakinumab and 0.7% with triamcinolone acetonide.
Incidencija bolesnika s povišenjima triglicerida >5 x gornja granica normale (GGN) bila je 2,4% s kanakinumabom i 0,7% s triamcinolon acetonidom.
Experience from individual patients who achieved a complete response following dose escalation to 600 mg (8 mg/kg) every 8 weeks suggests that a higher dose may be beneficial in patients not achieving complete response or not maintaining complete response with the recommended doses (150 mg or 2 mg/kg for patients ≥ 15 kg and ≤ 40 kg).
Iskustvo s pojedinačnim bolesnicima koji su postigli potpuni odgovor nakon povećanja doze na 600 mg (8 mg/kg) svakih 8 tjedana upućuje na to da bi viša doza mogla biti korisna kod bolesnika koji ne postignu potpun odgovor ili ne održavaju potpun odgovor s preporučenim dozama (150 mg ili 2 mg/kg za bolesnike ≥15 kg i ≤40 kg).
- Any unused medicine must be discarded after the dose has been injected.
Sav neiskorišteni lijek mora se baciti nakon ubrizgavanja doze.
Gouty arthritis There is no relevant use of Ilaris in the paediatric population in the indication gouty arthritis.
Urični artritis Nema relevantne primjene Ilarisa u pedijatrijskoj populaciji u indikaciji uričnog artritisa.
The active substance is canakinumab.
Djelatna tvar je kanakinumab.
A murine antimurine IL-1 beta antibody had no undesirable effects on fertility in male or female mice (see section 5.3).
Protutijelo na mišji IL-1 beta nije imalo neželjenih učinaka na plodnost mužjaka ili ženki miševa (vidjeti dio 5.3).
Treatment with Ilaris may result in dizziness/vertigo or asthenia (see section 4.8).
Liječenje Ilarisom može rezultirati omaglicom/vrtoglavicom ili astenijom (vidjeti dio 4.8).
Patients taking canakinumab in Part II had a 64% reduced risk of a flare event as compared to the placebo group (hazard ratio of 0.36; 95% CI: 0.17 to 0.75; p=0.0032).
Bolesnici koji su uzimali kanakinumab u drugom dijelu imali su za 64% smanjeni rizik od naglog pogoršanja bolesti u usporedbi s placebo skupinom (omjer hazarda 0,36; 95% CI: 0,17 do 0,75; p=0,0032).
The expression of hepatic CYP450 enzymes may be suppressed by the cytokines that stimulate chronic inflammation, such as interleukin-1 beta (IL-1 beta).
Ekspresiju jetrenih CYP450 enzima mogu potisnuti citokini koji stimuliraju kroničnu upalu, poput interleukina-1 beta (IL-1 beta).
Two non-randomised HIDS/MKD patients aged > 28 days but < 2 years were included in the study and received canakinumab.
Dva nerandomizirana bolesnika s HIDS/MKD-om u dobi od >28 dana ali <2 godine bila su uključena u ispitivanje i primala kanakinumab.
Tip the vial to ensure that the required amount of solution can be drawn into the syringe.
Nagnite bočicu kako biste osigurali da se potrebna količina otopine može uvući u štrcaljku.
Although ≥ Grade 2 reductions in neutrophil count occurred in 6.5% of patients (common) and Grade 1 reductions occurred in 9.5% of patients, the reductions are generally transient and neutropenia-associated infection has not been identified as an adverse reaction.
Iako su se smanjenja broja neutrofila ≥ stupnja 2 javila u 6,5% bolesnika (često), a smanjenja stupnja 1 u 9,5% bolesnika, smanjenja su općenito prolazna te infekcija povezana s neutropenijom nije utvrđena kao nuspojava.
The estimated steady state AUCtau was 636.7 ± 260.2 μg*d/ml.
Procijenjeni AUCtau u stanju dinamičke ravnoteže bio je 636,7 ± 260,2 μg*d/ml.
Hold the syringe at a 90-degree angle and in a single, smooth motion, push the needle straight down completely into the skin.
Držite štrcaljku pod kutom od 90 stupnjeva i jednim glatkim pokretom do kraja gurnite iglu okomito prema dolje u kožu.
The overall predicted mean (±SD) for Cmin,ss, Cmax,ss and AUC,ss4w were 14.7±8.8 μg/ml, 36.5 ± 14.9 μg/ml and 696.1 ± 326.5 μg*d/ml, respectively.
Ukupne predviđene srednje vrijednosti (±SD) za Cmin,ss, Cmax,ss i AUC,ss4w bile su 14,7±8,8 μg/ml, 36,5 ± 14,9 μg/ml odnosno 696,1 ± 326,5 μg*d/ml.
A 6-year observational registry study was conducted to provide data on the long-term safety and effectiveness of canakinumab treatment in paediatric and adult CAPS patients in routine clinical practice.
Provedeno je 6-godišnje opservacijsko ispitivanje u obliku registra (opservacijski registar) kako bi se dobili podaci o dugoročnoj sigurnosti i učinkovitosti liječenja kanakinumabom pedijatrijskih i odraslih bolesnika s CAPS-om u rutinskoj kliničkoj praksi.
Seventeen patients (including 6 patients under the age of 2 years) were evaluated, using weight-based starting doses of 2-8 mg/kg.
Bilo je ocijenjeno sedamnaest bolesnika (uključujući 6 bolesnika mlađih od 2 godine) uz početne doze od 2-8 mg/kg temeljene na tjelesnoj težini.
Make sure all of the solution is in the bottom of the vial.
13. Provjerite da je cjelokupna otopina na dnu bočice.
Disease activity was rated as absent or mild/moderate in more than 90% of patients at all post-baseline time points in the study, and median serological markers of inflammation (CRP and SAA) were normal (< 10 mg/litre) at all post-baseline time points.
Aktivnost bolesti je bila ocijenjena kao odsutna ili blaga/umjerena u više od 90% bolesnika u svim ispitivanim vremenskim točkama nakon početka ispitivanja i srednja vrijednost seroloških upalnih markera (CRP i SAA) je bila normalna (<10 mg/litra) u svim ispitivanim vremenskim točkama nakon početka.
Turn the vial and syringe upside down and bring to eye level.
Preokrenite bočicu sa štrcaljkom naopako i podignite je do razine očiju.
Allow to stand for about 15 minutes at room temperature to get a clear to opalescent solution.
Pustite da odstoji oko 15 minuta na sobnoj temperaturi kako biste dobili bistru do opalescentnu otopinu.